Bio-Path Holdings DEF 14A Filing
Ticker: BPTH · Form: DEF 14A · Filed: Oct 28, 2024 · CIK: 1133818
| Field | Detail |
|---|---|
| Company | Bio-Path Holdings, Inc. (BPTH) |
| Form Type | DEF 14A |
| Filed Date | Oct 28, 2024 |
| Risk Level | medium |
| Pages | 16 |
| Reading Time | 19 min |
| Key Dollar Amounts | $0.001, $9,500 |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance
TL;DR
Bio-Path Holdings DEF 14A filed. Annual meeting Dec 12. Vote your shares!
AI Summary
Bio-Path Holdings, Inc. filed a DEF 14A proxy statement on October 28, 2024, for its annual meeting on December 12, 2024. The filing details information for shareholders regarding the company's operations and governance, including matters to be voted on at the meeting. The company is involved in the pharmaceutical preparations industry.
Why It Matters
This filing provides shareholders with crucial information for voting on company matters, impacting corporate governance and future strategic decisions.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine but can contain information about significant corporate events or proposals that may affect stock price.
Key Numbers
- 2834 — SIC Code (Pharmaceutical Preparations industry)
Key Players & Entities
- BIO-PATH HOLDINGS, INC. (company) — Registrant
- 0001558370-24-013752 (filing_id) — Accession Number
- 20241028 (date) — Filing Date
- 20241212 (date) — Fiscal Year End / Meeting Date
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is used by companies to solicit shareholder votes on important corporate matters, such as the election of directors or approval of executive compensation.
When is Bio-Path Holdings, Inc.'s annual meeting scheduled?
The proxy statement indicates that the period of report is 20241212, suggesting the annual meeting is scheduled for December 12, 2024.
What industry is Bio-Path Holdings, Inc. in?
Bio-Path Holdings, Inc. is classified under the Standard Industrial Classification (SIC) code 2834, which pertains to Pharmaceutical Preparations.
What is the filing date of this DEF 14A?
This DEF 14A filing was made on October 28, 2024, as indicated by the accession number and filing values.
Where is Bio-Path Holdings, Inc. headquartered?
The company's business and mailing address is listed as 4710 BELLAIRE BOULEVARD, SUITE 210, BELLAIRE, TX 77401.
Filing Stats: 4,835 words · 19 min read · ~16 pages · Grade level 14.7 · Accepted 2024-10-28 16:32:26
Key Financial Figures
- $0.001 — f the Company's common stock, par value $0.001 per share, at a ratio of up to 1-for-30
- $9,500 — nual Meeting for a fee of approximately $9,500 plus out-of-pocket expenses. The Compa
Filing Documents
- tmb-20241212xdef14a.htm (DEF 14A) — 865KB
- tmb-20241212xdef14a_bg001.jpg (GRAPHIC) — 208KB
- tmb-20241212xdef14a_bg002.jpg (GRAPHIC) — 88KB
- 0001558370-24-013752.txt ( ) — 1266KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 12 PROPOSAL ONE: ELECTION OF DIRECTORS 13 Nominees for Directors 13 Required Vote 15 Recommendation of the Board 15 CORPORATE GOVERNANCE 16 General 16 Board Structure and Role in Risk Oversight 16 Director Independence 16 Board Composition and Diversity 17 Nomination Process 17 Stockholder Nominations for Directors 18 Board Committees and Other Information 18 Employee, Officer and Director Hedging 20 Availability of Committee Charters and Other Information 20 Communications with Directors 20 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 21 SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE 22 EXECUTIVE OFFICERS AND EXECUTIVE COMPENSATION 23 Executive Officers 23
Executive Compensation
Executive Compensation 23 Summary Compensation Table 27 Grants of Plan-Based Awards Table 27 Narrative Disclosures to Summary Compensation Table and Grants of Plan-Based Awards Table 28 Outstanding Equity Awards at December 31, 2023 28 Employment Agreement and Potential Payments Upon Termination or Change of Control 29 Pay Versus Performance Table 30 Narrative Disclosure to Pay Versus Performance Table 31 DIRECTOR COMPENSATION 32 Narrative to Director Compensation Table 33 PROPOSAL TWO: RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 34 Principal Accountant Fees and Services 34 Pre-Approval Policies and Procedures 34 Appointment for 2024 34 Required Vote 35 Recommendation of the Board 35 Table of Contents AUDIT COMMITTEE REPORT 36 PROPOSAL THREE: APPROVAL OF AN AMENDMENT TO THE COMPANY'S 2022 STOCK INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK THAT MAY BE ISSUED UNDER THE PLAN BY 1,200,000 SHARES FOR A TOTAL OF 1,265,000 SHARES 37 Material Terms of the 2022 Plan 37 Federal Income Tax Treatment of Awards under the 2022 Plan 40 New Plan Benefits 40 Existing Plan Benefits 40 Equity Compensation Plan Information 41 Required Vote 41 Recommendation of the Board 41 PROPOSAL FOUR: APPROVAL OF AMENDMENT TO THE COMPANY'S CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT OF THE COMPANY'S COMMON STOCK AT A RATIO OF UP TO 1-FOR-30, TO BE DETERMINED BY THE BOARD 42 Reasons for the Reverse Stock Split 42 Certain Risks Associated with the Reverse Stock Split 43 Determination of Reverse Stock Split Ratio 44 Impact of the Reverse Stock Split, if Implemented 44 Procedure for Effecting the Reverse Stock Split 45 Effect of Reverse Stock Split Resulting in Fractions of A Share 45 Effect on Certificated Shares 45 Effect on Registered "Book-Entry" Holders of Common Stock 46 Effect on Beneficial Ho